Cluster headache and galcanezumab: the first real-world Brazilian study and an expert consensus on its use among other treatments

Abstract Objective To present the first Brazilian real-world results with galcanezumab and provide a consensus expert opinion on the prophylactic treatment of cluster headache (CH) in Brazil. Methods The first part of the study (real-world results) was observational, prospective, uncontrolled, and d...

Full description

Bibliographic Details
Published in:	The Journal of Headache and Pain
Main Authors:	Abouch Krymchantowski, Carla Jevoux, Élcio Juliato Piovesan, Marcelo Moraes Valença, Fernando Kowacs, Pedro André Kowacs, Fabíola Dach, Paulo Hélio Monzillo, Carlos Alberto Bordini, Raimundo Pereira Silva-Néto
Format:	Article
Language:	English
Published:	BMC 2024-12-01
Subjects:	Cluster headache Treatment Galcanezumab Expert consensus Brazil
Online Access:	https://doi.org/10.1186/s10194-024-01909-w

Similar Items

Migren Profilaksisinde Etkili Bir Ajan; Galcanezumab: Tek Merkez Deneyimleri
by: Sena Boncuk Ulaş, et al.
Published: (2024-09-01)

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
by: Heejung Mo, et al.
Published: (2022-10-01)

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
by: Yanbo Yang, et al.
Published: (2020-02-01)

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
by: Simona Guerzoni, et al.
Published: (2023-06-01)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-10-01)

Safety and efficacy of galcanezumab in chronic and episodic migraine patients: a systematic review and meta-analysis of randomized controlled trials
by: Mohamed Sayed Zaazouee, et al.
Published: (2024-05-01)

Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study
by: Yooha Hong, et al.
Published: (2023-10-01)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
by: Kenta Kashiwagi, et al.
Published: (2023-02-01)

Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study
by: Oralee J. Varnado, et al.
Published: (2025-04-01)

Consensus of the Brazilian Headache Society on the treatment of chronic migraine
by: Fernando KOWACS, et al.

Medication-overuse headache. Retrospective comparison of preventive treatments
by: Abouch V. Krymchantowski, et al.

Medication-overuse headache—a review of different treatment strategies
by: Abouch Krymchantowski, et al.
Published: (2023-10-01)

Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation
by: Wanakorn Rattanawong, et al.
Published: (2025-01-01)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
by: Panagiotis Gklinos, et al.
Published: (2021-03-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-01-01)

Primary headache diagnosis among chronic daily headache patients
by: Abouch Valenty Krymchantowski
Published: (2003-06-01)

Efficacy of galcanezumab in migraine central sensitization
by: Daisuke Danno, et al.
Published: (2024-09-01)

Botulinum neurotoxin type-A for primary stabbing headache: an open study Toxina botulínica do tipo-A para o tratamento da cefaléia primária em punhaladas: um estudo aberto
by: Elcio Juliato Piovesan, et al.
Published: (2010-04-01)

Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat
by: Nadine Friedrich, et al.
Published: (2024-01-01)

Síndrome de S.U.N.C.T. Relato de um caso precedido de trauma ocular S.U.N.C.T. syndrome: report of a case preceded by ocular trauma
by: Elcio Juliato Piovesan, et al.
Published: (1996-09-01)

Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America
by: Rigmor Hoejland Jensen, et al.
Published: (2023-12-01)

Real-life experiences with galcanezumab and predictors for treatment response in Turkey
by: Pınar Yalinay Dikmen, et al.
Published: (2023-11-01)

Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
by: Keiko Ihara, et al.
Published: (2023-03-01)

O padrão biológico da cefaléia cervicogênica pode ser alterado pelo uso excessivo de ergotamínicos ou pela sua retirada? Can the biologic pattern of cervicogenic headache change after overuse or withdrawal of the ergotamine derivatives?
by: ELCIO JULIATO PIOVESAN, et al.
Published: (2000-06-01)

Usefulness of the Support Video “Talking Picture Book” for Overcoming Hesitancy to Start Galcanezumab Therapy
by: Hisanao Akiyama, et al.
Published: (2025-05-01)

Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study
by: Samuel Díaz Insa, et al.
Published: (2024-03-01)

Chronic unremitting headache associated with Lyme disease-like illness
by: Pedro Andre Kowacs, et al.
Published: (2013-07-01)

Cerebral Artery Vasoconstriction After Galcanezumab Loading Dose for Migraine Prevention: A Case Report
by: Thanin Asawavichienjinda, et al.
Published: (2024-10-01)

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
by: Jiying Zhou, et al.
Published: (2023-08-01)

In the era of monoclonal antibodies targeting the calcitonin gene-related peptide pathway, is it still necessary to stop taking excessive pain medication?
by: Renata Gomes Londero
Published: (2025-09-01)

Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study
by: Edina Szabo, et al.
Published: (2023-01-01)

Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II
by: Paulo Sergio Faro Santos, et al.
Published: (2022-09-01)

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry
by: Victor Obach, et al.
Published: (2023-11-01)

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
by: Hans-Christoph Diener, et al.
Published: (2025-02-01)

Oscillucusis and sudden deafness in a migraine patient Oscilucusia e perda auditiva em um paciente com migranea
by: Elcio Juliato Piovesan, et al.
Published: (2003-09-01)

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)
by: Fabrizio Vernieri, et al.
Published: (2024-02-01)

The Differences and Connections Among Expert Evidence, Expert Opinion and Expert Consensus in the Development of Guidelines
by: ZHU Di, et al.
Published: (2024-07-01)

Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
by: Mamoru Shibata, et al.
Published: (2023-09-01)

Central effects of galcanezumab in migraine: a pilot study on Steady State Visual Evoked Potentials and occipital hemodynamic response in migraine patients
by: Marina de Tommaso, et al.
Published: (2022-04-01)

Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine
by: Elif Ilgaz Aydinlar, et al.
Published: (2024-06-01)